NASDAQ:DBVT
DBV Technologies S.A. Stock News
$0.571
-0.123 (-17.77%)
At Close: May 09, 2024
28 Healthcare Stocks Moving In Thursday's Pre-Market Session
12:00am, Thursday, 05'th Mar 2020Why Aimmune Therapeutics Shares Fell 23.3% in February
10:36pm, Wednesday, 04'th Mar 2020
A risk management process slowed the launch of Aimmune’s first product.
DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update
09:30pm, Wednesday, 04'th Mar 2020
Montrouge, France, March 4, 2020 DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update Advisory Committee meeting to be held on May.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its pre
DBV Technologies Announces Partial Exercise of Underwriters' Option to Purchase Additional ...
12:00am, Monday, 02'nd Mar 202025 Healthcare Stocks Moving In Monday's Pre-Market Session
12:00am, Monday, 24'th Feb 2020DBV Technologies Press Release Confirms FDA AdCom Panel For Viaskin Peanut Candidate As May 15, 2020
12:00am, Friday, 21'st Feb 2020Perceptive Advisors Llc Buys Agios Pharmaceuticals Inc, Provention Bio Inc, Quotient, Sells ...
12:00am, Wednesday, 19'th Feb 2020DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference
12:00am, Monday, 10'th Feb 2020Bio Roundup: POTUS on Prices, a16z's Fund, Aimmune's Approval & More
12:48pm, Friday, 07'th Feb 2020
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics:
3 Biotechnology Stocks Moving In Tuesday's Pre-Market Session
12:00am, Tuesday, 04'th Feb 2020Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval
08:53pm, Saturday, 01'st Feb 2020
Shares of biopharma Aimmune Therapeutics Inc (NASDAQ: AIMT ) advanced strongly in after-hours trading Friday following a positive FDA verdict for Aimunne's peanut allergy drug. 9-Year Wait Ends The FD
